PD-1 Inhibitor Combined with Radiotherapy and GM-CSF with or not IL-2 (PRaG regimen) in Patients with Microsatellite Stable Metastatic Colorectal Cancer

被引：0
|
作者：
Yang, J. [1 ]
Xing, P. [1 ]
Kong, Y. [1 ]
Xu, M. [1 ]
Zhang, L. [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 2, Dept Radiotherapy & Oncol, Suzhou, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2341
引用
收藏
页码：E154 / E154
页数：1
相关论文
共 50 条
  • [1] PD-1 Inhibitor Combined with Radiotherapy and GM-CSF with or not IL-2 (PRaG Regimen) for Advanced Metastatic Non-Small Cell Lung Cancer
    Zhou, W.
    Kong, Y.
    LiYuan, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E402 - E402
  • [2] The response of PD-1 inhibitor combined with Radiotherapy and GM-CSF(PRaG) with or without IL-2 in microsatellite stable metastatic colorectal cancer: Analysis of pooled data from two phase II trials.
    Yang, Jiabao
    Zhou, Wei
    Ma, Yifu
    Su, Di
    Kong, Yuehong
    Xu, Meiling
    Xing, Pengfei
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15561 - E15561
  • [3] A phase II trial of PD-1 inhibitor combined with Radiotherapy and GM-CSF (PRaG) in metastatic tumors
    Zhang, L.
    Kong, Y.
    Xing, P.
    Zhao, X.
    Chen, G.
    Ma, Y.
    Zou, L.
    Peng, Q.
    Xu, M.
    Xu, Z.
    RADIOTHERAPY AND ONCOLOGY, 2021, 161 : S492 - S492
  • [4] PD-1 Inhibitor Combined with Hypofractionated Radiotherapy and GM-CSF with or without IL-2 (PRaG Regimens) Rechallenge for Acquiring Resistance to PD-1/ PD-L1 Inhibitor in Advanced Solid Tumors
    Xu, M.
    Xing, P.
    Kong, Y.
    Zhang, C.
    Zhao, X.
    Zhang, J.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E427 - E428
  • [5] PRaG regimens (PD-1 inhibitor combined with radiotherapy and GM-CSF with or not IL-2) rechallenge for patients with acquiring resistance to PD-1/PD-L1 inhibitors in refractory advanced solid tumors
    Xu, Meiling
    Xing, Pengfei
    Kong, Yuehong
    Zhang, Chenyang
    Zhao, Xiangrong
    Zhang, Junjun
    Zhang, Liyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] PD-1 Inhibitors Combined with Radiotherapy and GM-CSF, Sequentially Followed by IL-2 (PRaG 2.0) Regimen in Metastatic Tumors: A Prospective, Multicenter, Single-Arm Clinical Trial
    Xing, P.
    Yang, J.
    Xu, M.
    Kong, Y.
    Wang, J.
    Wang, J.
    Han, D.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E427 - E427
  • [7] A Prospective Clinical Trial of Radiotherapy Combined with PD-1 Inhibitors and GM-CSF, Sequentially Followed by IL-2 (PRaG 2.0) Regimen in Advanced Refractory Solid Tumors
    Xing, P.
    Yang, J., Sr.
    Xu, M.
    Kong, Y.
    Zhang, J.
    Zhao, X.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E157 - E158
  • [8] PD-1 Inhibitor Combined With Radiotherapy and GM-CSF (PRaG) in Patients With Metastatic Solid Tumors: An Open-Label Phase II Study
    Kong, Yuehong
    Zhao, Xiangrong
    Xu, Meiling
    Pan, Jie
    Ma, Yifu
    Zou, Li
    Peng, Qiliang
    Zhang, Junjun
    Su, Cunjin
    Xu, Zhi
    Zhou, Wei
    Peng, Yong
    Yang, Jiabao
    Zhou, Chengliang
    Li, Yujia
    Guo, Qiuchen
    Chen, Guangqiang
    Wu, Hongya
    Xing, Pengfei
    Zhang, Liyuan
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report
    Yang, Jiabao
    Xing, Pengfei
    Kong, Yuehong
    Xu, Meiling
    Zhang, Liyuan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [10] A Phase II Trial of PD-1 Inhibitors Combined With Multisite Radiotherapy and GM-CSF (PRaG Regimen) for the Treatment of Chemo-Refractory Metastatic Solid Tumors
    Kong, Y.
    Xing, P.
    Zhao, X.
    Chen, G.
    Ma, Y.
    Zhou, L.
    Peng, Q.
    Xu, M.
    Xu, Z.
    Zhang, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S117 - S117
12345